Abstract:
Objective To explore the efficacy and safety of thymalfasin in the treatment of severe pulmonary infection after liver transplantation.
Methods Twenty seven patients who developed severe lung infection after undergoing liver transplantation in Organ Transplant Institute of the 309th Hospital of People's Liberation Army from January 2008 to May 2014 were enrolled in this study. According to whether the application of thymalfasin, the patients were divide into thymalfasin group(n=11) and control group(n=16). In the thymalfasin group, thymalfasin was administered via subcutaneous injection at a dose of 1.6 mg once daily for consecutive two weeks. In the control group, conventional anti-infection therapy was delivered. Ventilator time, duration of fever, the length of intensive care unit(ICU) stay and mortality were statistically compared between two groups. And the incidence of acute rejection (AR) was monitored.
Results Ventilator time, duration of fever, length of ICU stay of patients in the thymalfasin group were significantly shortened compared with those in the control group (all in P < 0.05). There was no significant difference in the mortality between two groups. No clinical AR was observed in either group. No thymalfasin-related adverse event was found in the thymalfasin group.
Conclusions Thymalfasin can improve the curative effect to anti-infection of patients with severe pulmonary infection after liver transplantation without the incidence of AR, which is efficacious and safe in the treatment of severe pulmonary infection.
下载: